HOMEVULNERABILITIESCVE-2026-33185
MEDIUM

CVE-2026-33185

CWE-918Published: March 31, 2026· Updated: Apr 1, 2026

5.3
CVSS v3.1
EPSS:0.04%probability of exploitation in 30 daysPercentile:11.7th

Official Description

Discourse is an open-source discussion platform. From versions 2026.1.0-latest to before 2026.1.3, 2026.2.0-latest to before 2026.2.2, and 2026.3.0-latest to before 2026.3.0, the group email settings test endpoint could be used to make the server initiate outbound connections to arbitrary hosts and ports. This could allow probing of internal network infrastructure. The endpoint was accessible to non-staff group owners. This issue has been patched in versions 2026.1.3, 2026.2.2, and 2026.3.0.

NVD Source

Technical Analysis

CVE-2026-33185 can be exploited remotely over the network without requiring physical or adjacent access, significantly expanding the attack surface for threat actors.

Exploitation requires low privileges, which limits the exposure to scenarios where an attacker has already gained initial access.

CVSS v3.1 Vector Breakdown

Exploitability
Attack VectorNetwork
Attack ComplexityLow
Privileges Req.Low
User InteractionNone
ScopeX
Impact
Confidentiality
Integrity
Availability
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:L/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Exploit & PoC Resources

NO KNOWN EXPLOITNo public exploit confirmed at this time
External links open in a new tab. Always verify in a controlled environment before use.

All References (2)

Quick Facts

CVE IDCVE-2026-33185
CVSS Score5.3 / 10
SeverityMEDIUM
WeaknessCWE-918
CISA KEVNo
EPSS (30d)0.04%
PublishedMar 31, 2026

Related CVEs (CWE-918)

Recommended Actions

  • Apply vendor patches immediately
  • Monitor CVE-2026-33185 in threat intel feeds
  • Review IDS/IPS signatures for exploitation attempts
Data sourced from NVD (NIST), CISA KEV, and EPSS (FIRST). Analysis generated by CTIWATCH.COM. CVE data is provided under the NVD usage policy.